Scottish Childhood Obesity Treatment Trial
Completed
- Conditions
- Nutritional, Metabolic, EndocrineObesity
- Registration Number
- ISRCTN41383109
- Lead Sponsor
- Yorkhill Hospitals NHS Trust (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 134
Inclusion Criteria
Obese (body mass index [BMI] greater than 98th percentile) children of primary school age (5 - 11 years at baseline), referred for treatment for their obesity.
Exclusion Criteria
1. Non obese
2. Family apparently not willing to attempt lifestyle changes
3. Having special educational needs
4. Receiving treatment for obesity elsewhere
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Body mass index (BMI) standard deviation score.<br><br>Outcomes measured at baseline, +6 months after start of intervention and +12 months after start of intervention.
- Secondary Outcome Measures
Name Time Method 1. Objectively measured habitual physical activity and sedentary behaviour (accelerometry)<br>2. Waist circumference standard deviation score<br>3. Quality of life<br><br>Outcomes measured at baseline, +6 months after start of intervention and +12 months after start of intervention.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the Scottish Childhood Obesity Treatment Trial's intervention strategies?
How does the intervention in ISRCTN41383109 compare to standard-of-care treatments for pediatric obesity in terms of efficacy and metabolic impact?
Are there specific biomarkers identified in the Scottish Childhood Obesity Treatment Trial that correlate with treatment response in metabolic syndrome or insulin resistance subtypes?
What adverse events were observed in ISRCTN41383109 and how do they compare to other pediatric obesity interventions like GLP-1 receptor agonists?
What combination therapies or related compounds have been explored alongside interventions in ISRCTN41383109 for addressing leptin resistance or adipokine dysregulation in childhood obesity?